Novel strategy for the gene concerning chemoresistance in pancreas cancer

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592023
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Nagoya University
• Principal Investigator: KOKURYO TOSHIO 名古屋大学, 医学(系)研究科(研究院), 特任講師 (60378023)
• Co-Investigator(Kenkyū-buntansha): NAGINO Masato 名古屋大学, 医学系研究科, 教授 (20237564) ; YOKOYAMA Yukihiro 名古屋大学, 医学部附属病院, 講師 (80378091) ; SENGA Takeshi 名古屋大学, 医学系研究科, 准教授 (80419431) ; ITATSU Keita 名古屋大学, 医学部附属病院, 助教 (90534842) ; SHIMIZU Yasuhiro 愛知県がんセンター, 消化器外科, 部長 (40470166)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 膵癌 / 治療抵抗性遺伝子 / TPX2 / IGFBP-3

Outline of Final Research Achievements

The targeting protein for Xklp2 (TPX2) is a microtubule- and, cell cycle- associated protein who’s overexpression has been reported in various malignancies. TPX2 was overexpressed in both surgically resected specimens of pancreatic cancer and multiple pancreatic cancer cell lines. TPX2 siRNA effectively suppressed the proliferation of pancreatic cancer cells in culture, and the direct injection of TPX2 siRNA into subcutaneously implanted pancreatic cancer cells in nude mice revealed anti-proliferative effects. Insulin-like growth factor binding protein-3 (IGFBP-3) was significantly higher in TPX2 siRNA-treated tumors than in the Control siRNA-treated tumors.
Our study revealed that the anti-angiogenic effect observed in TPX2 siRNA-treated pancreatic cancer cells may be partly explained by the upregulation of IGFBP-3.

Free Research Field

外科腫瘍学